evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

251 questions · 255 findings · 24 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 61 · 23.9%GRADE not reported 40 · 15.7%Very low 45 · 17.6%Low 56 · 22%Moderate 38 · 14.9%High 15 · 5.9%

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

Overall mortality · patients with acquired SAA

First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in overall mortality compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).

1 finding from 1 review

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

Secondary clonal disease or malignancies · patients with acquired SAA

First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in secondary clonal disease or malignancies compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).

1 finding from 1 review

Plerixafor vs placebo

Successful stem cell collection · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma

Plerixafor leads to higher successful stem cell collection compared with placebo (high certainty).

1 finding from 1 review

Plerixafor vs placebo

Adverse events (during stem cell mobilisation and collection) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma

Plerixafor showed no clear difference in adverse events (during stem cell mobilisation and collection) compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Stem Cell vs placebo or control

CDAI <150 at 24 weeks · Induction of Remission in Medically Refractory Crohn's Disease

It is very uncertain whether summary of findings table ‐ Stem Cell changes CDAI <150 at 24 weeks compared with placebo or Control (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Stem Cell vs placebo or control

Fistula Closure short‐term · Induction of Remission in Medically Refractory Crohn's Disease

Summary of findings table ‐ Stem Cell may leads to higher fistula Closure short‐term compared with placebo or Control (low certainty).

1 finding from 1 review

Summary of findings table ‐ Stem Cell vs placebo or control

Fistula closure in long‐term · Induction of Remission in Medically Refractory Crohn's Disease

Summary of findings table ‐ Stem Cell may leads to higher fistula closure in long‐term compared with placebo or Control (low certainty).

1 finding from 1 review

Summary of findings table ‐ Stem Cell vs placebo or control

Total adverse events · Induction of Remission in Medically Refractory Crohn's Disease

It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).

1 finding from 1 review